TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Study of 5-FU Continuous Infusion (5-FUci) Versus CPT-11 Plus CDDP (CP) Versus S-1 Alone (S-1) in Advanced Gastric Cancer (JCOG9912)
Brief Summary: To investigate the superiority of a combination of irinotecan and cisplatin and the non-inferiority of S-1 compared to continuous infusion of 5-FU in advanced gastric cancer


Options:
A: Arm Label: CapeOx plus Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib, Drug: Capecitabine, Drug: Oxaliplatin | Arm Label: CapeOx plus Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Capecitabine, Drug: Oxaliplatin | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): CapeOx plus Lapatinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CapeOx plus Placebo | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): CapeOx plus Lapatinib, CapeOx plus Placebo | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): CapeOx plus Lapatinib, CapeOx plus Placebo
B: Arm Label: Arm A: De-escalation therapy; Type: EXPERIMENTAL; Interventions: Drug: S-1 de-escalation | Arm Label: Arm B: Chemotherapy by Investigator's choice; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy by Investigator's choice | Intervention Type: DRUG; Name: S-1 de-escalation; Assigned to Arm(s): Arm A: De-escalation therapy | Intervention Type: DRUG; Name: Chemotherapy by Investigator's choice; Assigned to Arm(s): Arm B: Chemotherapy by Investigator's choice
C: Intervention Type: DRUG; Name: continuous infusion of 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: combination of irinotecan and cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oral administration of S-1; Assigned to Arm(s): N/A
D: Arm Label: Arm A, - Modified DCF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin | Arm Label: ARM B - Parent DCF with G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen | Arm Label: Arm C - Modifid DCF + Trastuzumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab | Intervention Type: DRUG; Name: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Assigned to Arm(s): Arm A, - Modified DCF | Intervention Type: DRUG; Name: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen; Assigned to Arm(s): ARM B - Parent DCF with G-CSF | Intervention Type: DRUG; Name: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab; Assigned to Arm(s): Arm C - Modifid DCF + Trastuzumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Maternal and Infant Immunization Strategies to Prevent Pneumococcal Disease
Brief Summary: This prospective randomized evaluation of pneumococcal vaccine immunization of pregnant mothers, followed by pneumococcal conjugate immunization of their children is designed to assess the effects of these strategies on the immunogenicity and safety of both vaccines. We hypothesize that maternal followed by infant immunization will be safe and will provide higher levels of antibody from birth through 12 months of age.


Options:
A: Arm Label: Trivalent Influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent Influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline
B: Intervention Type: BIOLOGICAL; Name: pneumococcal polysaccharide and protein conjugate vaccines; Assigned to Arm(s): N/A
C: Arm Label: Trivalent influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Influenza Vaccine Intervention; Type: EXPERIMENTAL; Interventions: Other: Influenza Vaccine Intervention | Intervention Type: OTHER; Name: Influenza Vaccine Intervention; Assigned to Arm(s): Influenza Vaccine Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Examining Psychosocial Mediators of Exercise Behavior
Brief Summary: The purpose of this study is to examine psychosocial mediators of exercise behavior.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: Endurance respiratory muscle training; Type: EXPERIMENTAL; Interventions: Other: Endurance respiratory muscle training | Arm Label: Resistance inspiratory muscle training; Type: ACTIVE_COMPARATOR; Interventions: Other: Resistance inspiratory muscle training | Intervention Type: OTHER; Name: Endurance respiratory muscle training; Assigned to Arm(s): Endurance respiratory muscle training | Intervention Type: OTHER; Name: Resistance inspiratory muscle training; Assigned to Arm(s): Resistance inspiratory muscle training
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Wellness | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Wellness; Assigned to Arm(s): 2
D: Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional chest physiotherapy | Arm Label: Training Group; Type: EXPERIMENTAL; Interventions: Other: Conventional chest physiotherapy, Other: Inspiratory muscle training | Intervention Type: OTHER; Name: Conventional chest physiotherapy; Assigned to Arm(s): Control Group, Training Group | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Training Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Bupropion Used in Combination With the Nicotine Replacement Patch and Cognitive Behavioral Therapy for Treating Nicotine Dependent Individuals - 1
Brief Summary: Existing and new pharmacotherapies along with prevention efforts are key to improving smoking cessation rates and reducing the premature morbidity and mortality associated with tobacco use. A number of individuals suffer from both nicotine dependence and depression. The purpose of this study is to determine the effectiveness of bupropion used in combination with the nicotine replacement patch and cognitive behavior therapy (CBT) in treating nicotine dependent individuals also diagnosed with depression.


Options:
A: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Intervention Type: DRUG; Name: Pharmacotherapies for Smoking Cessation; Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: SSR591813L (dianicline); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Bupropion Used in Combination With the Nicotine Replacement Patch and Cognitive Behavioral Therapy for Treating Nicotine Dependent Individuals - 1
Brief Summary: Existing and new pharmacotherapies along with prevention efforts are key to improving smoking cessation rates and reducing the premature morbidity and mortality associated with tobacco use. A number of individuals suffer from both nicotine dependence and depression. The purpose of this study is to determine the effectiveness of bupropion used in combination with the nicotine replacement patch and cognitive behavior therapy (CBT) in treating nicotine dependent individuals also diagnosed with depression.


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
B: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Intervention Type: DRUG; Name: Pharmacotherapies for Smoking Cessation; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Bupropion Used in Combination With the Nicotine Replacement Patch and Cognitive Behavioral Therapy for Treating Nicotine Dependent Individuals - 1
Brief Summary: Existing and new pharmacotherapies along with prevention efforts are key to improving smoking cessation rates and reducing the premature morbidity and mortality associated with tobacco use. A number of individuals suffer from both nicotine dependence and depression. The purpose of this study is to determine the effectiveness of bupropion used in combination with the nicotine replacement patch and cognitive behavior therapy (CBT) in treating nicotine dependent individuals also diagnosed with depression.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Intervention Type: DRUG; Name: Pharmacotherapies for Smoking Cessation; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Bupropion Used in Combination With the Nicotine Replacement Patch and Cognitive Behavioral Therapy for Treating Nicotine Dependent Individuals - 1
Brief Summary: Existing and new pharmacotherapies along with prevention efforts are key to improving smoking cessation rates and reducing the premature morbidity and mortality associated with tobacco use. A number of individuals suffer from both nicotine dependence and depression. The purpose of this study is to determine the effectiveness of bupropion used in combination with the nicotine replacement patch and cognitive behavior therapy (CBT) in treating nicotine dependent individuals also diagnosed with depression.


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Intervention Type: DRUG; Name: Pharmacotherapies for Smoking Cessation; Assigned to Arm(s): 1, 2
C: Arm Label: Nicotine Patch (4 weeks); Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Nicotine Patch (8 weeks); Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch (4 weeks), Nicotine Patch (8 weeks)
D: Arm Label: Selegiline Transdermal Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Selegiline Transdermal Patch, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Selegiline Transdermal Patch; Assigned to Arm(s): Selegiline Transdermal Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Placebo, Selegiline Transdermal Patch

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Bupropion Used in Combination With the Nicotine Replacement Patch and Cognitive Behavioral Therapy for Treating Nicotine Dependent Individuals - 1
Brief Summary: Existing and new pharmacotherapies along with prevention efforts are key to improving smoking cessation rates and reducing the premature morbidity and mortality associated with tobacco use. A number of individuals suffer from both nicotine dependence and depression. The purpose of this study is to determine the effectiveness of bupropion used in combination with the nicotine replacement patch and cognitive behavior therapy (CBT) in treating nicotine dependent individuals also diagnosed with depression.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Intervention Type: DRUG; Name: Pharmacotherapies for Smoking Cessation; Assigned to Arm(s): 1, 2
B: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Clinical Efficacy, Safety, and Immunogenicity of a Human Cocaine Vaccine (TA-CD) in the Treatment of Cocaine Dependence
Brief Summary: The purpose of this study is to test the efficacy of a newly developed active vaccine against cocaine (TA-CD).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Killed bivalent whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli Placebo | Intervention Type: BIOLOGICAL; Name: Killed bivalent whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli | Intervention Type: BIOLOGICAL; Name: killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli; Assigned to Arm(s): 2
C: Arm Label: Placebo injection; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Injection | Arm Label: TA-CD Vaccination; Type: EXPERIMENTAL; Interventions: Drug: TA-CD Vaccination | Intervention Type: DRUG; Name: TA-CD Vaccination; Assigned to Arm(s): TA-CD Vaccination | Intervention Type: OTHER; Name: Placebo Injection; Assigned to Arm(s): Placebo injection
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: bivalent killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: bivalent killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Breaking Down Barriers to Diabetes Self-Care
Brief Summary: Performance of self-care recommendations is key to the successful treatment of diabetes. However, many patients have difficulty adhering to diabetes self-care recommendations. Recent results from our own studies and others have identified specific barriers to diabetes self-care. To evaluate the efficacy of a diabetes educator-led group intervention, the Breaking Down Barriers Program, that addresses barriers and therefore leads to improved adherence to diabetes self-care recommendations, we will randomize 222 (111 type 1 and 111 type 2) diabetes patients to one of three conditions: 1) the Breaking Down Barriers Program, 2) a cholesterol attention control condition, or 3) a 'usual care' control condition. We hypothesize that those assigned to the Breaking Down Barriers group will improve self-care behaviors and glycemic control more than those in the two control groups. We will follow study subjects for one year to determine whether their self-care behaviors and glycemic control improved and if the improvement was maintained over time.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Breaking Down Barriers | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breaking Down Barriers | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breaking Down Barriers | Intervention Type: BEHAVIORAL; Name: Breaking Down Barriers; Assigned to Arm(s): 1, 2, 3
B: Arm Label: telecoaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: telecoaching | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telecoaching; Assigned to Arm(s): telecoaching
C: Arm Label: Geriatric Diabetes Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral | Arm Label: Atention Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral; Assigned to Arm(s): Geriatric Diabetes Team Intervention
D: Arm Label: dashboard team care intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Dashboard Intervention | Arm Label: usual diabetes team control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Diabetes Care | Intervention Type: BEHAVIORAL; Name: Diabetes Dashboard Intervention; Assigned to Arm(s): dashboard team care intervention | Intervention Type: BEHAVIORAL; Name: Usual Diabetes Care; Assigned to Arm(s): usual diabetes team control

Answer: A